GeneDx Reports Third Quarter 2026 Financial Results
Business Wire•09/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $123.1 million, up 5% year-over-year
- ➤Exome and genome revenue $110.4 million, up 12% year-over-year
- ➤Exome and genome volume grew 25% year-over-year to 32,134 tests
- ➤Adjusted gross margin expanded to 72%; adjusted net income reached $8.6 million
- ➤2026 revenue guidance reiterated at $475 million to $490 million
Expert Statements
Katherine Stueland, CEO of GeneDx
“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth.”
Katherine Stueland, CEO of GeneDx
“Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale.”
Katherine Stueland, CEO of GeneDx
“By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”
* Reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue
* Reported exome and genome volume growth of 25% year-over-year with accession growth of 28% year-over-year
Get started
Create a free account to read the full story.